title: Vascular endothelial cells have impaired capacity to present immunodominant, antigenic peptides: a mechanism of cell type-specific immune escape.
abstract: Vascular endothelial cells (EC) are an exposed target tissue in the course of CTL-mediated alloimmune diseases such as graft-vs-host disease (GVHD) or solid organ transplant rejection. The outcome of an interaction between CTL and target cells is determined by the amount of Ag presented and the costimulatory signals delivered by the target cells. We compared human EC with leukocytes and epithelial cells as targets for peptide-specific, MHC class I-restricted CTL clones. EC were poor targets for immunodominant CTL. Both endogenously processed antigenic proteins and exogenously added antigenic peptides are presented at 50- to 5000-fold lower levels on EC compared with any other target cell analyzed. This quantitative difference fully explained the poor CTL-mediated killing of EC. There was no evidence that lack of costimulation would contribute significantly to this cell type-specific difference in CTL activation. An HLA-A2-specific CTL clone that killed a broad selection of HLA A2-positive target cells equally well, killed EC less efficiently. Our data suggest that EC present a different Ag repertoire compared with other cell types. By this mechanism, these cells may escape an attack by effector CTL, which have been educated by professional APCs and are specific for immunodominant antigenic peptides.
authors.affiliation: Department of Medicine, University Hospital Bruderholz, Bruderholz, Switzerland.
authors.forename: Marco
authors.initials: M
authors.lastname: Kummer
authors.forename: Avital
authors.initials: A
authors.lastname: Lev
authors.forename: Yoram
authors.initials: Y
authors.lastname: Reiter
authors.forename: Barbara C
authors.initials: BC
authors.lastname: Biedermann
mesh_terms: D017951:Antigen Presentation / Q000276:immunology*; D000954:Antigens, Surface / Q000096:biosynthesis; D016923:Cell Death / Q000276:immunology; D002461:Cell Line, Transformed; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D002999:Clone Cells; D003601:Cytotoxicity Tests, Immunologic; D004730:Endothelium, Vascular / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D018984:Epitopes, T-Lymphocyte / Q000276:immunology / Q000378:metabolism; D005260:Female; D015789:HLA-A2 Antigen / Q000276:immunology / Q000378:metabolism; D056466:Histone Demethylases; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D007111:Immunity, Cellular; D016056:Immunodominant Epitopes / Q000276:immunology* / Q000378:metabolism*; D008297:Male; D015778:Minor Histocompatibility Antigens; D010446:Peptide Fragments / Q000276:immunology* / Q000378:metabolism*; D011506:Proteins / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D000954:Antigens, Surface; D018984:Epitopes, T-Lymphocyte; D015789:HLA-A2 Antigen; D016056:Immunodominant Epitopes; D015778:Minor Histocompatibility Antigens; D010446:Peptide Fragments; D011506:Proteins; D056466:Histone Demethylases; C095561:KDM5D protein, human; D011495:Histone-Lysine N-Methyltransferase